Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma

Allergy and Asthma Proceedings

Volumn 28, Issue 5, 2007, Pages 550-556

  Ishizuka, Tamotsu ^a   Hisada, Takeshi ^a   Aoki, Haruka ^a   Yanagitani, Noriko ^a   Kaira, Kyoichi ^a   Utsugi, Mitsuyoshi ^a   Shimizu, Yasuo ^a   Sunaga, Noriaki ^a   Dobashi, Kunio ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Age; Asthma; Dose response; Dry powder inhaler; Dysphonia; Fluticasone propionate; Gender; Hoarseness; Inhaled corticosteroid; Risk factor

Indexed keywords

EID: 36649012783     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap2007.28.3049     Document Type: Article

References (29)

1. Barnes PJ, Pedersen S, and Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157:S1-S53, 1998.
2. Mash B, Bheekie A, and Jones PW. Inhaled vs oral steroids for adults with chronic asthma. Cochrane Database Syst Rev 1:CD002160, 2001.
3. Dubus JC, Marguet C, Deshildre A, et al. Local side effects of inhaled corticosteroids in asthmatic children: Influence of drug, dose, age, and device. Allergy 56:944-948, 2001.
4. Johnson M. The anti-inflammatory profile of fluticasone propionate. Allergy 50(suppl 23):11-14, 1995.
5. Hogger P, and Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 59: 597-602, 1994.
6. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 101:5434-5439, 1998.
7. Powell N, Till SJ, Kay AB, et al. The topical glucocorticoids beclomethasone dipropionate and fluticasone propionate inhibit human T-cell allergen-induced production of IL-5, IL-3, and GM-CSF mRNA and protein. Clin Exp Allergy 31:69-76, 2001.
8. Stellato C, Atsuta J, Bickel CA, et al. An in vitro comparison of commonly used topical glucocorticoid preparations. J Allergy CHn Immunol 104:623-629, 1999.
9. Hagan JB, Kita H, and Gleich GJ. Inhibition of interleukin-5 mediated eosinophil viability by fluticasone 17-propionate: Comparison with other glucocorticoids. Clin Exp Allergy 28: 999-1006, 1998.
10. Adams N, Bestall JM, Lasserson TJ, et al. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2:CD002310, 2005.
11. Ministry of Health and Welfare, Japan. Asthma prevention and management guidelines. Int Arch Allergy Immunol 121(suppl 1):1-77, 2000.
12. Toogood JH, Baskerville J, Jennings B, et al. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 84:688-700, 1989.
13. Lavy JA, Wood G, Robin JS, et al. Dysphonia associated with inhaled steroids. J Voice 14:581-588, 2000.
14. Kriz RJ, Chmelik R, and Do Pico G. A one-year trial of triamcinolone acetonide aerosol in severe steroid-dependent asthma. Chest 72:36-44, 1977.
15. Williamson IJ, Matusiewicz SP, Brown PH, et al. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J 8:590-592, 1995.
16. Williams AJ, Baghat MS, Stableforth DE, et al. Dysphonia caused by inhaled steroids: Recognition of a characteristic laryngeal abnormality. Thorax 38:813-821, 1983.
17. Toogood JH, Jennings B, Greenway RW, et al. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol 102:592-594, 1980.
18. Pingleton WW, Bone RC, Kerby GR, et al. Oropharyngeal candidiasis in patients treated with triamcinolone acetonide aerosol. J Allergy Clin Immunol 60:254-258, 1977.
19. DelGaudio JM. Steroid inhaler laryngitis: Dysphonia caused by inhaled fluticasone therapy. Arch Otolarygol Head Neck Surg 128:677-681, 2002.
20. Gallivan GJ, Gallivan KH, and Gallivan HK. Inhaled corticosteroids: Hazardous effects on voice-an update. J Voice 21:101-111, 2007.
21. Borgström L, Bondesson E, Morén F, et al. Lung deposition of budesonide inhaled via Turbuhaler: A comparison with terbutaline sulphate in normal subjects. Eur Respir J 7:69-73, 1994.
22. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 84(suppl A):25-29, 1990.
23. Nielsen LP, and Dahl R. Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med 162:2053-2057, 2000.
24. Berend N, Kellett B, Kent N, et al. Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate. Respirology 6:237-246, 2001.
25. Barnes NC, Hallett C, and Harris TA. Clinical experience with fluticasone propionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 92:95-104, 1998.
26. Adams N, Bestall J, and Jones PW. Inhaled fluticasone propionate for chronic asthma. Cochrane Database Syst Rev 3:CD003135, 2001.
27. Engel T, Heinig JH, Mailing H-J, et al. Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler. Allergy 44:220-225, 1998.
28. Thompson PJ, Davies RJ, Young WF, et al. Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med 92(suppl A):33-39, 1998.
29. Lyseng-Williamson KA, and Keating GM. Inhaled salmeterol/ fluticasone propionate combination in chronic obstructive pulmonary disease. Am J Respir Med 1:273-282, 2002.